Literature DB >> 16596316

The use of chronobiotics in the resynchronization of the sleep-wake cycle.

Daniel P Cardinali1, Analía M Furio, María P Reyes, Luis I Brusco.   

Abstract

Treatment of circadian rhythm disorders, whether precipitated by intrinsic factors (e.g., sleep disorders, blindness, mental disorders, aging) or by extrinsic factors (e.g., shift work, jet-lag) has led to the development of a new type of agents called 'chronobiotics', among which melatonin is the prototype. The term 'chronobiotic' defines as a substance capable of shifting the phase of the circadian time system thus re-entraining circadian rhythms. Melatonin administration synchronizes the sleep-wake cycle in blind people and in individuals suffering from delayed sleep phase syndrome or jet lag, as well in shift-workers. The effect of melatonin on sleep is probably the consequence of increasing sleep propensity (by inducing a fall in body temperature) and of a synchronizing effect on the circadian clock (chronobiotic effect). We successfully employed the timely use of three factors (melatonin treatment, exposure to light, physical exercise) to hasten the resynchronization after transmeridian flights comprising 12-13 time zones, from an average of 8-10 days to about 2 days. Daily melatonin production decreases with age, and in several pathologies, attaining its lowest values in Alzheimer's dementia patients. About 45% of dementia patients have severe disruptions in their sleep-wakefulness cycle. Both in aged subjects having very minimal sleep disorders as well as in demented patients with a very severe disorganization of the sleep-wake cycle, melatonin treatment reduced the variability of sleep onset and restored sleep.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16596316     DOI: 10.1007/s10552-005-9009-2

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  10 in total

1.  Melatonin: a non-benzodiazepine hypnotic in an elderly blind female with dementia.

Authors:  Colm Devine
Journal:  Ther Adv Psychopharmacol       Date:  2011-06

2.  How to fix a broken clock.

Authors:  Analyne M Schroeder; Christopher S Colwell
Journal:  Trends Pharmacol Sci       Date:  2013-10-10       Impact factor: 14.819

3.  Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Authors:  Venkatramanujam Srinivasan; Daniel P Cardinali; Uddanapalli S Srinivasan; Charanjit Kaur; Gregory M Brown; D Warren Spence; Rüdiger Hardeland; Seithikurippu R Pandi-Perumal
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

Review 4.  The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis.

Authors:  Ingeborg M van Geijlswijk; Hubert P L M Korzilius; Marcel G Smits
Journal:  Sleep       Date:  2010-12       Impact factor: 5.849

Review 5.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 6.  Role of the melatonin system in the control of sleep: therapeutic implications.

Authors:  Seithikurippu R Pandi-Perumal; Venkatramanujan Srinivasan; D Warren Spence; Daniel P Cardinali
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  Therapeutic applications of melatonin.

Authors:  Ifigenia Kostoglou-Athanassiou
Journal:  Ther Adv Endocrinol Metab       Date:  2013-02       Impact factor: 3.565

Review 8.  A molecular and chemical perspective in defining melatonin receptor subtype selectivity.

Authors:  King Hang Chan; Yung Hou Wong
Journal:  Int J Mol Sci       Date:  2013-09-06       Impact factor: 5.923

9.  Melatonin in mitochondrial dysfunction and related disorders.

Authors:  Venkatramanujam Srinivasan; D Warren Spence; Seithikurippu R Pandi-Perumal; Gregory M Brown; Daniel P Cardinali
Journal:  Int J Alzheimers Dis       Date:  2011-05-04

10.  Melatonin, immune function and aging.

Authors:  V Srinivasan; G J M Maestroni; D P Cardinali; A I Esquifino; S R Pandi Perumal; S C Miller
Journal:  Immun Ageing       Date:  2005-11-29       Impact factor: 6.400

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.